C4 Therapeutics Statistics
Total Valuation
C4 Therapeutics has a market cap or net worth of $112.19 million. The enterprise value is -$58.15 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
C4 Therapeutics has 71.01 million shares outstanding. The number of shares has increased by 28.41% in one year.
| Current Share Class | 71.01M |
| Shares Outstanding | 71.01M |
| Shares Change (YoY) | +28.41% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 3.66% |
| Owned by Institutions (%) | 71.02% |
| Float | 46.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.78 |
| Forward PS | 6.45 |
| PB Ratio | 0.57 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.70, with a Debt / Equity ratio of 0.33.
| Current Ratio | 5.70 |
| Quick Ratio | 5.47 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.55% and return on invested capital (ROIC) is -24.80%.
| Return on Equity (ROE) | -45.55% |
| Return on Assets (ROA) | -20.30% |
| Return on Invested Capital (ROIC) | -24.80% |
| Return on Capital Employed (ROCE) | -41.82% |
| Revenue Per Employee | $361,664 |
| Profits Per Employee | -$938,882 |
| Employee Count | 110 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.
| Income Tax | 131,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.35% in the last 52 weeks. The beta is 3.11, so C4 Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 3.11 |
| 52-Week Price Change | -74.35% |
| 50-Day Moving Average | 1.72 |
| 200-Day Moving Average | 4.14 |
| Relative Strength Index (RSI) | 49.59 |
| Average Volume (20 Days) | 1,335,397 |
Short Selling Information
The latest short interest is 6.41 million, so 9.02% of the outstanding shares have been sold short.
| Short Interest | 6.41M |
| Short Previous Month | 7.73M |
| Short % of Shares Out | 9.02% |
| Short % of Float | 13.75% |
| Short Ratio (days to cover) | 4.96 |
Income Statement
In the last 12 months, C4 Therapeutics had revenue of $39.78 million and -$103.28 million in losses. Loss per share was -$1.48.
| Revenue | 39.78M |
| Gross Profit | -75.39M |
| Operating Income | -116.56M |
| Pretax Income | -106.59M |
| Net Income | -103.28M |
| EBITDA | -114.73M |
| EBIT | -116.56M |
| Loss Per Share | -$1.48 |
Full Income StatementBalance Sheet
The company has $215.09 million in cash and $64.37 million in debt, giving a net cash position of $170.34 million or $2.40 per share.
| Cash & Cash Equivalents | 215.09M |
| Total Debt | 64.37M |
| Net Cash | 170.34M |
| Net Cash Per Share | $2.40 |
| Equity (Book Value) | 195.14M |
| Book Value Per Share | 2.75 |
| Working Capital | 191.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$80.32 million and capital expenditures -$180,000, giving a free cash flow of -$80.50 million.
| Operating Cash Flow | -80.32M |
| Capital Expenditures | -180,000 |
| Free Cash Flow | -80.50M |
| FCF Per Share | -$1.13 |
Full Cash Flow StatementMargins
Gross margin is -189.51%, with operating and profit margins of -292.99% and -259.60%.
| Gross Margin | -189.51% |
| Operating Margin | -292.99% |
| Pretax Margin | -259.27% |
| Profit Margin | -259.60% |
| EBITDA Margin | -288.40% |
| EBIT Margin | -292.99% |
| FCF Margin | n/a |
Dividends & Yields
C4 Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.41% |
| Shareholder Yield | -28.41% |
| Earnings Yield | -92.05% |
| FCF Yield | -71.76% |
Analyst Forecast
The average price target for C4 Therapeutics is $12.50, which is 691.14% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.50 |
| Price Target Difference | 691.14% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 126.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
C4 Therapeutics has an Altman Z-Score of -1.57 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.57 |
| Piotroski F-Score | 4 |